New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
08:04 EDTICAD, PHGiCAD, Invivo announce global strategic agreement for MRI solutions
Invivo, a Philips Healthcare Business (PHG), and iCAD, Inc. (ICAD) announced that the companies have entered into a global research, development, and commercial agreement. Under the agreement, iCAD will develop advanced MRI image analysis software products which Invivo will incorporate into its suite of MRI product solutions for global commercial sale. The first products are anticipated to be available in Q2 2013. The initial focus of the partnership will be the release of a next generation platform for prostate and breast imaging. Additional new product releases are also anticipated beginning the second half of 2013.
News For ICAD;PHG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2015
10:00 EDTPHGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aegerion (AEGR) upgraded to Buy from Hold at Jefferies... Ameren (AEE) upgraded to Neutral from Sell at Goldman... AutoNation (AN) upgraded to Buy from Neutral at Sterne Agee CRT... Beacon Roofing (BECN) upgraded to Outperform at Baird... BlackBerry (BBRY) upgraded to Equal Weight from Underweight at Morgan Stanley... Bojangles (BOJA) upgraded to Buy from Neutral at SunTrust... Boyd Gaming (BYD) upgraded to Neutral from Underperform at BofA/Merrill... Columbus McKinnon (CMCO) upgraded to Buy from Neutral at Sidoti... Danaher (DHR) upgraded to Overweight from Equal Weight at Morgan Stanley... Emerald Oil (EOX) upgraded to Hold from Sell at Wunderlich... Haemonetics (HAE) upgraded Outperform from Market Perform at Barrington... Jefferies sees entry point for Aegerion (AEGR), upgrades to Buy... Philips (PHG) upgraded to Buy from Hold at Societe Generale... Plum Creek Timber (PCL) upgraded to Buy from Neutral at DA Davidson... Raytheon (RTN) upgraded to Buy from Neutral at BofA/Merrill... SandRidge Energy (SD) upgraded to Hold from Sell at Wunderlich... Telecom Argentina (TEO) upgraded to Outperform from Market Perform at Raymond James... Teva (TEVA) upgraded to Outperform from Market Perform at BMO Capital... Triumph Bancorp (TBK) upgraded to Buy from Hold at Evercore ISI... Waste Management (WM) upgraded on valuation, rebounding businesses at Argus... Wisconsin Energy (WEC) upgraded to Buy from Neutral at Goldman.
06:12 EDTPHGPhilips upgraded to Equal Weight from Underweight at Barclays
Subscribe for More Information
06:11 EDTPHGPhilips upgraded to Buy from Hold at Societe Generale
July 24, 2015
07:45 EDTPHGPhilips management to meet with JPMorgan
Subscribe for More Information
July 21, 2015
07:17 EDTPHGPhilips announces collaboration with Profound Medical
Subscribe for More Information
07:16 EDTPHGPhilips announces joint development agreement with Profound Medical
Royal Philips and Profound Medical Corp, a Toronto-based medical device company, announced that they have signed a joint development agreement to support Profound Medical’s proprietary TULSA technology designed to treat patients with prostate cancer on Philips’ Ingenia and Achieva 3T MRI systems. Profound Medical will soon release 12 month data from its 30 patient safety and feasibility study with the goal of obtaining a CE mark and commercialization of TULSA-PRO in Europe and Canada in 2016.
July 15, 2015
10:05 EDTPHGPhilips says study shows NIPPV helps reduce COPD readmissions by 97%
Philips co-authored and funded a study in the "Journal of Clinical Sleep Medicine" that highlights non-invasive ventilation as a key part of a multi-faceted intervention approach to successfully reduce readmission rates among COPD patients. The study evaluated COPD patients who were hospitalized two or more times within a year and transitioned to a COPD patient management program, which included treating those same patients with noninvasive positive pressure ventilation, or NIPPV. The results of the study showed that the readmission rate was reduced by 97% during the subsequent 12 months. The study used Philips Respironics Trilogy 100 to deliver the NIPPV therapy to the study patients. The study, entitled "Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease" and authored by Steven Coughlin, PhD, Wei Liang, PhD and Sairam Parthasarathy, MD, examined 397 patients who had all been hospitalized at least twice in a single year with an acute COPD exacerbation. Each patient was prescribed a Trilogy ventilator manufactured by Philips Respironics for home use. Continued in home care consisted of medication management, oxygen therapy, patient education and ongoing respiratory therapist care in the home.
July 14, 2015
08:04 EDTICADiCAD launches new cervical applicator for Xoft Axxent system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use